RANITIDINE 300MG TAB

Each 300 mg film-coated tablet contains: Ranitidine 300 mg (Equivalent to Ranitidine hydrochloride 355.0 mg USP ).

17.25 EGP

Purchase this product now and earn 17 Points!

RANITIDINE 300MG TAB; ranitidine, gastrointestinal agents .

ACTIVE-INGREDIENT OF RANITIDINE 300MG TAB

Each 300 mg film-coated tablet contains: Ranitidine 300 mg (Equivalent to Ranitidine hydrochloride 355.0 mg USP ).

INDICATION OF RANITIDINE 300MG TAB

1. Short -term treatment of active duodenal ulcer : Most patients heal within 4 weeks. Studies available to date have not assessed the safety of ranitidine is uncomplicated duodenal ulcer for periods of more than 8 weeks. 2. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. No placebo-controlled comparative studies have been carried out for periods of longer than 1 years. 3. The treatment of pathological hypersecretory conditions ( e.g. Zollinger-Ellison syndrome and systemic mastocytosis). 4. Short-term treatment of active, benign gastric ulcer. Most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. Studies available to date have not assessed the safety of ranitidine is uncomplicated bengin gastric ulcer for periods of more than 6 weeks . 5. Maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. Placebo-controlled studies have been carried out for 1 year. 6. Treatment of GERD. Symptomatic relief commonly occurs within 24 hours after starting therapy with RANTIDOL 150 mg twice daily. 7. Treatment of endoscopically diagnosed erosive esophagitis. Symptomatic relief of heartburn commonly occurs within 24 hours of therapy initiation with RANTIDOL 150 mg four times daily. 8. Maintenance of healing of erosive esophagitis . Placebo-controlled trials have been carried out for 48 weeks. Concomitant antacids should be given as needed for pain relief to patients with active duodenal ulcer; active, benign gastric ulcer; hypersecretory states; GERD; and erosive esophagitis.

DOSAGE OF RANITIDINE 300MG TAB

Follow all directions given to you by your pharmacist or doctor carefully . They may differ from the information contained in this leaflet

Ask your pharmacist or doctor for help if you do not understand the instructions on the box .

The recommended dose is : –

Adults Oral Formulations : Duodenal ulcer and benign gastric ulcer: Acute treatment : The standard dosage regimen for duodenal or benign gastric ulcer is RANITIDINE 150 mg twice daily or 300 mg nocte, in most cases of duodenal ulcer and benign gastric ulcer , healing occurs within 4 weeks. Healing usually occurs after a further 4 weeks in those not healed after the initial 4 weeks. In duodenal ulcer 300 mg twice daily for four weeks results in healing rates which are higher than those at four weeks with RANITIDINE 150 mg twice daily or 300 mg nocte. The increased dose has not been associated with an increased incidence of unwanted effects. Long term: For the long-term management of Duodenal ulcer and benign gastric ulcer the usual dosage regimen is 150 mg nocte, smoking is associated with a higher rate of duodenal ulcer relapse, and such patients should be advised to stop smoking. In those who fail to comply with such advice a dose of 300 mg nocte provides additional therapeutic benefit over the 150 mg dosage regimen. NSAID associated peptic ulceration: Acute treatment: 150 mg twice daily for 8 to 12 weeks, or 300 mg nocte. Prophylaxis: For the prevention of non-steroidal anti-inflammatory drug associated duodenal ulcers RANITIDINE 150 mg twice daily may be given concomitantly with non-steroidal anti-inflammatory drug therapy. Duodenal ulcer associated with Helicobacter pylori infection: RANITIDINE 300 mg at bedtime or 150 mg twice daily may be given with the oral amoxicillin 750 mg three times daily and, metronidazole 500 mg three times. Post-operative ulcer: The standard dosage regimen for post-operative ulcer is 150 mg twice daily, most cases treat within 4 weeks, those not fully healed after the initial four weeks usually do so after a further four weeks. Gastro-oesophageal Reflux Disease: Acute treatment: 150 mg twice daily or 300 mg nocte is administered for up to a period of 8 or if necehaemorrhage from stress ssary, 12 weeks. In patients with moderate to severe oesophagitis, the dosage of RANITIDINE may be increased 150 mg four times daily for up to 12 weeks. Long term management: For the long-term management of reflux oesophagitis the recommended adult oral dose is 150 mg twice daily. Symptom relief: For the relief of symptoms associated with oesophageal acid reflux, the recommended regimen is 150 mg twice daily for two weeks. This regimen may be continued for a further two weeks in those patients in whom the initial response is inadequate. Zoilinger-Ellison syndrome: The initial dosage regimen for Zollinger-Ellison Syndrome is 150 mg three times daily, but this may be increased as necessary. Doses up to 6 grams per day have been well tolerated. Chronic episodic dyspepsia: The standard dosage regimen for patients with chronic episodic dyspepsia is 150 mg twice daily for up to 6 weeks. Anyone not responding or relapsing shortly afterwards should be investegated. Prophylaxis of Mendelson’s syndrome: 150 mg 2 hours before anaesthesia, and preferably 150 mg the previous evening. In obestetric patients in labour 150 mg every 6 h, but if general anaesthesia is required it is recommended that a non-particulate antacid { e.g. sodium citrate} be given in addition. Prophylaxis haemorrhage from stress ulceration in seriously ill patients: 150 mg twice daily may be substituted for the injection once oral feeding commences. Renal impairment: Accumulation of ranitidine with resulting elevated plasma concentrations will occur In patients with severe renal impairment {creatinine clearance less than 50 ml/min}. It is recommended that the orally dose of RANITIDINE in such patients should be 150 mg. and that RANITIDINE injection be administered in doses of 25 mg.

OVER-DOSAGE OF RANITIDINE 300MG TAB

Ranitidine is very specific in action and no particular problems are expected following overdosage with Ranitidine formulations, Symptomatic and supportive therapy should be given as appropriate.

CONTRA-INDICATION OF RANITIDINE 300MG TAB

RANITIDINE products are contraindicated in patients known to have hypersensitivity to any component of the preparation.

STORAGE OF RANITIDINE 300MG TAB

RANITIDINE film-coated tablets should be stored at a temperature below 30 °C.
PACK OF RANITIDINE 300MG TAB
Box contains: 1 strip of 10 film coated tablets.
RANITIDINE 300MG TAB MANUFACTURED BY
Medical Union Pharmaceuticals Abu – Sultan, Ismailia, Egypt.

https://www.fda.gov/news-events/press-announcements/fda-requests-removal-all-ranitidine-products-zantac-market

https://www.gardeniapharmacy.com/category/medicine-2/

Form

Gender

How to use

Reviews

There are no reviews yet.

Be the first to review “RANITIDINE 300MG TAB”

Your email address will not be published.

Shopping Cart
Don`t copy text!
Scroll to Top